Lanean...
FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...
Gorde:
| Argitaratua izan da: | Mol Oncol |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026866/ https://ncbi.nlm.nih.gov/pubmed/29573334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12194 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|